TAVR in Bicuspid Valves: Higher Prosthesis Mismatch?

TAVR indication is steadily advancing onto younger, lower risk patients. 

¿El TAVI en válvulas bicúspides presenta mayor mismatch protésico?

The presence of bicuspid aortic valves (BAV) has been observed in 0.5% to 2% of echocardiograms and autopsies. We know this is a challenging anatomy for TAVR, because of greater calcification, which has been associated to increased complications and even higher mortality in the midterm, in some registries. Another potential issue is prosthetic mismatch (PPM), linked to worse evolution at long term. 

This analysis of the OCEAN TAVI registry included 7,051 patients, 503 (7.13%) presenting BAV aortic stenosis (AS), and the rest a tricuspid aortic valve (TAV) AS. Balloon expandable (BEV) Sapien XT and Sapien 3, and self-expanding valves (SEV) CoreValve and Evolut R/PRO were used. 

Read also: ROLLER COASTR-EPIC22: Comparison of Plaque Modification Techniques in Severely Calcified Coronary Lesions.

The heterogeneous groups were matched using propensity score, leaving 497 in each one. Mean patient age was 84, over 60% were women, mortality STS was 6%, 62% presented hypertension, 22% diabetes, 15% atrial fibrillation, and 67% kidney function deterioration. 

The transfemoral approach was used in 97% of cases, with no differences in type or valve diameter; the most used in both groups was the 29 mm valve. During the procedure, major and minor bleeding were more frequent among TAV patients (7.2% vs. 3%, p=0.003; 6% vs. 2.2%, p=0.002, respectively). There were no differences in aortic root lesion, coronary obstruction, conversion to surgery, stroke, life threatening bleeding, vascular complications or need for pacemaker implantation. Hospital stay was similar. 

At 30 days, mortality was 1% in both groups. 

Read also: Edge-to-Edge Repair in Central and Non-Central Mitral Regurgitation.

At two year followup, there were no differences in mortality, effective aortic area, indexed area, peak velocity or mean gradient. However, the presence of PPM was higher among TAV patients (moderate PPM 11.7% vs. 4.4%, severe 1.4% vs. 1%; p=0.001). PPM seemed associated to higher mortality, though with no statistical significance (p=0.065), and in the propensity score matched population, there was no significant impact (p=0.90).

Conclusion

Severe prosthetic mismatch could be associated to all-cause mortality, However, moderate and severe prosthetic mismatch was more frequent in patients with tricuspid aortic stenosis, vs bicuspid. 

Original Title: Incidence and Prognosis of Prosthesis-Patient Mismatch After Transcatheter Aortic Valve Replacement for Bicuspid Aortic Stenosis

Reference: Futoshi Yamanaka, et al. JACC Cardiovasc Interv. 2025;18:492–502.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Carlos Fava
Dr. Carlos Fava
Member of the Editorial Board of solaci.org

More articles by this author

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Percutaneous Tricuspid Valve Replacement with Lux-Valve

Tricuspid regurgitation (TR) is a condition associated with poor quality of life, frequent hospitalizations due to heart failure, and increased mortality, even under optimal...

TAVR in Small Annuli: What Valve Should We Use?

One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

ACC 2025 | TAVI in Low-Risk Patients: 5-Year Outcomes of EVOLUTE LOW RISK

Transcatheter aortic valve implantation (TAVI) is a valid alternative to surgery in low-risk patients with severe aortic stenosis. However, one of its main limitations...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Pretreatment with DAPT in Acute Coronary Syndrome: An Ongoing Debate?

In acute coronary syndrome (ACS) dual antiplatelet therapy (DAPT) has become a fundamental pillar after percutaneous coronary intervention (PCI), preventing stent thrombosis and acute...

Measuring Post-TAVI Gradients and Their Implications: Are Invasive and Echocardiographic Assessments Comparable?

Transcatheter aortic valve implantation (TAVI) is considered the treatment of choice for a significant proportion of patients with symptomatic aortic stenosis. Outcomes have improved...

Another Blow for Intra-Aortic Balloon Pumo Counterpulsation? Randomized Study on Its Use in Chronic Heart Failure Progressing to Cardiogenic Shock

Cardiogenic shock (CS) remains a condition with extremely high mortality (around 50%). While most therapies for this pathology have been studied in CS secondary...